Sunlands Technology Group Announces $15 Million Share Repurchase Program

PR Newswire

BEIJING, Dec. 6, 2021 /PRNewswire/ — Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), a leader in China’s online post-secondary and professional education, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to US$15 million of its Class A ordinary shares in the form of American depositary shares over the next 24 months.

Mr. Tongbo Liu, Chief Executive Officer of Sunlands, said, “The share repurchase program reflects the strength of our capital position and confidence in delivering sustained, long-term performance for our shareholders. We are pleased that our strong cash generating ability enables us to return value to shareholders as well as continue to invest in enhancing our content, upgrading our technology, and attracting more students to our platform to sustainably grow our business.”

The Company’s proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission (the “SEC”) Rule 10b-18 requirements. It is also expected that such repurchases will be effected pursuant to a plan in conformity with SEC Rule 10b5-1. The Company plans to fund repurchases from its existing cash balance.

About Sunlands

Sunlands Technology Group (NYSE: STG) (“Sunlands” or the “Company”), formerly known as Sunlands Online Education Group, is the leader in China’s online post-secondary and professional education. With a one to many, live streaming platform, Sunlands offers various degree and diploma-oriented post-secondary courses as well as online professional courses and educational content, to help students prepare for professional certification exams and attain professional skills. Students can access its services either through PC or mobile applications. The Company’s online platform cultivates a personalized, interactive learning environment by featuring a virtual learning community and a vast library of educational content offerings that adapt to the learning habits of its students. Sunlands offers a unique approach to education research and development that organizes subject content into Learning Outcome Trees, the Company’s proprietary knowledge management system. Sunlands has a deep understanding of the educational needs of its prospective students and offers solutions that help them achieve their goals.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Sunlands may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Sunlands’ beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: Sunlands’ goals and strategies; its expectations regarding demand for and market acceptance of its brand and services; its ability to retain and increase student enrollments; its ability to offer new courses and educational content; its ability to improve teaching quality and students’ learning results; its ability to improve sales and marketing efficiency and effectiveness; its ability to engage, train and retain new faculty members; its future business development, results of operations and financial condition; its ability to maintain and improve technology infrastructure necessary to operate its business; competition in the online education industry in China; relevant government policies and regulations relating to Sunlands’ corporate structure, business and industry; and general economic and business condition in China. Further information regarding these and other risks, uncertainties or factors is included in the Sunlands’ filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and Sunlands does not undertake any obligation to update such information, except as required under applicable law.

For investor and media enquiries, please contact:

Sunlands Technology Group
Investor Relations
Email: [email protected]

The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
Email: [email protected]

Yang Song

Tel: +86-10-6508-0677
Email: [email protected]

Cision View original content:

SOURCE Sunlands Technology Group

Houlihan Lokey Completes Integration of GCA, Establishing Global Leadership in Technology and Mid-Cap Corporate Finance

Houlihan Lokey Completes Integration of GCA, Establishing Global Leadership in Technology and Mid-Cap Corporate Finance

Houlihan Lokey (NYSE:HLI), the global investment bank, has successfully completed the acquisition of GCA Corporation (GCA). Following the acquisition of outstanding shares of GCA last month, the two companies will now move forward together as one firm under the Houlihan Lokey banner.

“With 500 new colleagues around the world having now joined Houlihan Lokey, we are better positioned than ever to deliver the superior client service on which we pride ourselves,” said Scott Beiser, CEO of Houlihan Lokey. “The outstanding cultural fit between the two firms has already contributed meaningfully to our successful integration, and we look forward to working together with our new partners across Europe, the U.S., and the Asia-Pacific region and realizing the substantial advantages that this combination has created,” he added.

Following this integration, Houlihan Lokey is now:

  • The most active technology M&A advisor in the world, with a Technology Group consisting of 225 financial professionals across a global network of now 38 offices around the globe1
  • The No. 1 most active global M&A advisor1
  • The No. 1 most active advisor to private equity globally2

“Today is a momentous day for the firm, as we are now able to work seamlessly with our new partners across regions, products, and sectors to establish the most client-focused, independent advisory firm in the investment banking arena. Houlihan Lokey is now the most active technology advisor in the world as well as a global leader in industrials; business services; consumer, food, and retail; healthcare; and financial services M&A. This combination also has created the largest private capital markets advisory group among our peers,” said Scott Adelson, Co-President of Houlihan Lokey.

“Geographically, the addition of these talented colleagues makes us one of the largest advisors in Europe and also has firmly cemented our position as the most active M&A advisor in the U.S. In addition, we now have an expanded platform from which to grow our business in the Asia-Pacific region.

“We will continue to build on these leading positions and draw on both our shared corporate culture and the immense pool of intellectual capital that lies at the core of our advisory services,” he continued.

Though the two firms now operate together under the Houlihan Lokey brand in Europe and the United States, the brand transition in Asia is expected to take place early in 2022.

1 Source: Mergermarket, excludes Accounting firms.

2 Source: PitchBook.

About Houlihan Lokey

Houlihan Lokey (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and valuation. The firm serves corporations, institutions, and governments worldwide with offices in the United States, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. Houlihan Lokey is the No. 1 M&A advisor for the past six consecutive years in the U.S., the No. 1 global restructuring advisor for the past seven consecutive years, and the No. 1 global M&A fairness opinion advisor over the past 20 years, all based on number of transactions and according to data provided by Refinitiv.

Investor Relations


[email protected]

Media Relations

Richard Creswell

+44 (0) 20 7747 1480

John Gallagher


[email protected]

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance


Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021

  • First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated
  • All patients exhibited reductions in viral load and complete COVID-19 clinical symptom recovery
  • Additional data presented includes review of the supportive Phase 1 study of ensovibep in healthy volunteers
  • Global Phase 2-3 EMPATHY clinical study for ambulatory COVID-19 patients ongoing with topline data available in early 2022

ZURICH-SCHLIEREN, Switzerland and CONCORD Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients as well as additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference.

The single arm Phase 2a study enrolled 12 patients, all of whom were confirmed as positive for COVID-19 with mild to moderate symptoms. The single center study was designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep. The results were presented by study investigator Dr. Johan van der Plas from the Centre for Human Drug Research (CHDR), Leiden, the Netherlands;

  • First ensovibep data from COVID-19 infected patients: 225 mg and 600 mg doses were seen to be safe and well tolerated
    • No disease enhancement, infusion related reactions, or dose limiting toxicities observed
  • Viral load data (qPCR) showed a comparable decline for both dose levels
  • Infectivity of virus extracted through nasopharyngeal swabs was reduced to zero within 3-5 days post treatment in patients with positive titers at baseline.
  • Favorable PK profile in patients consistent with the profile observed in healthy volunteers: Confirmation of half-life and prolonged therapeutic exposure >2 weeks in all dosed patients
  • Complete COVID-19 clinical symptom recovery in the study population

These findings support large-scale controlled evaluation of ensovibep as a treatment for mild-to-moderate COVID-19.

“As global COVID-19 cases continue to rise, with many countries under-vaccinated and new variants such as Delta and Omicron spreading quickly and affecting millions of lives, it is imperative that we find therapeutics designed to combat this virus as well as its future mutations,” said Dr Lutz Hegemann, Group Head of Corporate Affairs and Global Health for Novartis, Molecular Partners’ COVID-19 collaboration partner. “These data further support ensovibep’s potential as a valuable treatment option for COVID-19 patients and we look forward to reviewing the results from the ongoing, global Phase 2-3 trial, EMPATHY.”

Molecular Partners also presented additional data from the Phase 1, randomized, double-blind, placebo-controlled single ascending dose study for safety, tolerability, and pharmacokinetics of intravenously administered ensovibep, which indicated that it was well tolerated with a half-life in the range of 2-3 weeks.

“These data characterize the safety and pharmacodynamic profile of ensovibep in ambulatory COVID-19 patients and provide an early insight into the antiviral activity of ensovibep, as we await a major data read-out from our global EMPATHY study in early 2022,” said Patrick Amstutz, CEO of Molecular Partners. “We remain confident that ensovibep’s unique tri-specific mechanism, designed to maintain potency against viral mutations and its potential for a one-time simple administration make it a differentiated therapeutic candidate that could help combat this ongoing threat.”

Presentation details:

Phase 1 Poster:

Title: Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose study
Presenter: Marianne Soergel, Molecular Partners AG, Schlieren, Switzerland
Date and time: Monday 6 December, 12:00 – 13:45 CET

Phase 2 Oral Presentation

Title: Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 – preliminary report of a phase 2a, open-label, single dose escalation study.
Presenter: J.L. van der Plas, Centre for Human Drug Research (CHDR), Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands
Date and time: Monday 6 December, 18:00 – 19:45 CET

Ensovibep is currently being evaluated in EMPATHY, a global Phase 2-3 study designed to explore the use of ensovibep for the treatment of COVID-19 in patients who are in the early stages of infection to prevent worsening symptoms and hospitalization. Molecular Partners’ collaboration partner, Novartis, is conducting the clinical trial for ensovibep, with Molecular Partners as a sponsor. The Phase 2b portion of EMPATHY enrolled patients across six countries. Topline data for the first 400 patients are expected in early 2022.

Based on continued evaluation of ensovibep, it maintains full potency in vitro against the individual positions of relevance to ensovibep that are mutated in the Omicron variant. Testing has been initiated in order to confirm the potency of ensovibep against a full Omicron pseudotype virus that includes all mutations simultaneously. In previous studies, ensovibep has maintained activity in vitro against all variants of concern detected, including the Delta strain.

About Molecular Partners AG 

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.; Find us on Twitter – @MolecularPrtnrs

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, “would” and similar expressions, and are based on Molecular Partners AG’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from our expectations include our plans to develop and potentially commercialize our product candidates; our reliance on third party partners and collaborators over which we may not always have full control; our ongoing and planned clinical trials and preclinical studies for our product candidates; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and ability to achieve market acceptance of our product candidates; our plans and development of any new indications for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position; our ability to identify and in-license additional product candidates; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners’ Registration Statement on Form F-1 filed with Securities and Exchange Commission (SEC) on June 14, 2021 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners’ website at Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further details, please contact:
Seth Lewis
[email protected] 
Tel: +1 781 420 2361

Shai Biran, Ph.D.
[email protected] 
Tel: +1 978 254 6286

Thomas Schneckenburger, European IR & Media
[email protected] 
Tel: +41 79 407 9952

Duolingo Reveals the “Most 2021 Phrase” and Launches Second Global Language Report

End of year campaign showcases most popular language courses, phrases and reasons people use the world’s leading mobile language learning platform

PITTSBURGH, Dec. 06, 2021 (GLOBE NEWSWIRE) — Duolingo (NASDAQ: DUOL), the world’s #1 language learning platform, this week revealed the “Most 2021 Phrase” which is “I’m mentally exhausted”. Duolingo selected this phrase, found in its Japanese course, to reflect the tone and overall feeling of the year in which we witnessed record-setting burnout and fatigue induced by the ongoing pandemic.

Alongside the “Most 2021 Phrase”, Duolingo also launched the company’s second global Language Report, which examines the latest language trends and learner behaviors based on data from over 500 million Duolingo learners around the globe who have downloaded the app. In 2021, over 700 million hours were spent learning on Duolingo with nearly 10 billion lessons completed and 15 billion words learned. Almost 25 million people worldwide were learning more than one language. Duolingo has more insight into global language learning trends than any other entity in history and the 2021 Language Report provides thoughtful analysis and unique insights into what learners want to study and why.

This year’s results clearly show that learners continue turning to languages to build bridges with cultures and people, across distances we can’t quite traverse in person — yet. Key findings reveal:

  • Asian language learning is skyrocketing — Japanese is the fastest growing language being learned this year in the US, with Korean rising in popularity around the world as well.
  • Family and heritage drives language learning in the U.S. — Family has suddenly surpassed school and brain training to become the most popular reason new learners in the U.S. are studying languages. Seventy percent of those who started learning a language during the pandemic say their learning is related to family heritage, ancestry or culture, according to a recent survey conducted in conjunction with the 2021 Duolingo Language Report.
  • Spanish still leads the way — The top five languages learned on Duolingo this year in the U.S. are Spanish, English, French, Japanese and German.

“We saw record growth of new learners studying a language in 2020, fueled by the pandemic, and now we’re able to share insights on how these patterns have evolved this year,” said Cindy Blanco, senior learning scientist. “One of the most interesting trends we saw this year was an increase in learners who were studying a language in order to connect with family. It’s been exciting to see people use language as a way to reconnect across cultures and relationships.”

Additionally, Duolingo is rolling out a new Year in Review experience which provides a visualized deep dive on individual user activity, showcasing eight different types of learners based on a variety of factors including hours spent learning, number of courses a learner has taken, what time a learner tends to practice, and more.

“This year, we’re rolling out personalized learner styles that give our learners a unique look at their learning habits, and we hope this inspires them to set new language learning goals for 2022,” said Blanco.

The Year in Review experience is available for all Duolingo learners who completed at least 10 lessons in 2021. Duolingo learners can see their personalized Year in Review snapshot in the app and can share their learner style directly to social media.

About Duolingo

Duolingo is the most popular language-learning platform and the most downloaded education app worldwide. The app makes learning new languages fun with bite-sized lessons that feel like playing a game. The company’s mission is to develop the best education in the world and make it universally available. Duolingo offers over 100 total courses across 40 distinct languages, from Spanish, French, German and Japanese, to Klingon.

Press Contact:

Sam Dalsimer,
Global Head of Communications
[email protected]

Audacy Rocks Fort Lauderdale Beach for Inaugural “Audacy Beach Festival”

Audacy Rocks Fort Lauderdale Beach for Inaugural “Audacy Beach Festival”

Performances from Twenty One Pilots, Lil Nas X, Weezer, The Lumineers, Glass Animals and More Fill Weekend of Music on the Sand

Audacy rocked a weekend of live music on the beach during its inaugural “Audacy Beach Festival” in Fort Lauderdale, FL on December 4 and 5. The two-day event was powered by performances from Twenty One Pilots, Lil Nas X, Weezer, The Lumineers, Glass Animals, Modest Mouse, Bleachers, Steve Aoki, AJR, Bastille, Yungblud, Walk the Moon, Cold War Kids, Tai Verdes, MOD SUN, Milky Chance, Willow, Beabadoobee, Cannons, The Regrettes, girl in red and Daisy the Great.

“After years of our popular Riptide event, we could not have been more excited to get back to the beach for a weekend of fun on the sand with our fans for the first ever ‘Audacy Beach Festival,’” said Michael Martin, Senior Vice President of Programming and Music Initiatives, Audacy. “We can all do a little more to help protect and preserve our planet, and this event allowed us to unite with five great partners to promote easy, sustainable practices to live healthier lifestyles.”

With the sun beaming down on day one of Audacy Beach Festival, Glass Animals elevated the crowd with their top hit “Heat Waves.” Later, fans were dancing throughout an epic performance from Steve Aoki before The Lumineers serenaded attendees with new music from their upcoming album “Brightside.” Twenty One Pilots closed out the evening with top hits and surprise covers from various artists during a campfire acoustic set. Day two continued with jams from artists like Cold Ward Kids, Bastille and Yungblud, before Lil Nas X delivered an electric performance of Grammy Award-nominated “Montero.” AJR helped wrap the two-day festival with a “Bang” before Weezer sent the South Florida crowd to “Beverly Hills” and into a frenzy with their renditions of Metallica’s “Enter Sandman” and Toto’s “Africa” to close the night.

For a collection of photos from Saturday, please click here. For a collection of photos from Sunday, please click here.

As part of Audacy’s 1Thing sustainability initiative to promote positive environmental practices and living, “Audacy Beach Festival” committed a portion of ticket sales to support REVERB, a 501c3 nonprofit dedicated to empowering millions of individuals to take action toward a better future for people and the planet, and its Music Climate Revolution campaign focused clean energy and carbon fighting projects. Audacy’s 1Thing initiative also teamed up with Celebration of the Sea Foundation (CSF), the Guy Harvey Ocean Foundation (GHOF), Faith Farm Ministries, and Conservation International to promote ocean conservation and sustainability. Sustainability practices included paperless tickets, digital signage, refill water stations, and more. Proceeds of the event’s reusable water bottles sold benefitted ocean conservation and educational initiatives through the CSF and GHOF. Excess food was rescued by Faith Farm Ministries and a donation to Conservation International will plant a tree for every festival attendee.

Audacy is committed to supporting the health and success of the communities that are the heart of its business. “Audacy Beach Festival” is a part of Audacy Serves, the Company’s social impact platform that raises awareness of social issues and brings communities together for good. Audacy unites with its listeners and brands to support sound communities through several pillars of impact: mental health and anti-bullying, veterans and service members, children’s health, the environment, civic education, and diversity, equity and inclusion.

About Audacy

Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country’s best radio broadcasting group, a leader in virtually every segment of audio, and America’s #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at, Facebook (Audacy Corp) and Twitter (@AudacyCorp).

Ashok Sinha



[email protected]

Meredith Tiger



[email protected]

David Heim



[email protected]

KEYWORDS: United States North America Florida Pennsylvania

INDUSTRY KEYWORDS: Entertainment Environment TV and Radio General Entertainment Celebrity Music Events/Concerts



Willis Towers Watson expands aviation insurance broking expertise and solutions with acquisition of Aerosure

Acquisition cements WTW’s position as a leading aviation broker in Asia and Australasia

SYDNEY, Australia, Dec. 05, 2021 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, today announced the acquisition of Aerosure, a leading aviation industry specialist, focused on the Australia, New Zealand and Pacific Island region.

Aerosure, based in Sydney, will become a part of Willis Towers Watson’s (WTW) Global Aerospace business, providing a suite of aviation insurance broking solutions to service the insurance and risk needs of the aviation industry in Australia and New Zealand, as well as the broader Asia Pacific region. Greg Rector, current Managing Director of Aerosure, will move into WTW as Managing Director, Australasia Aviation Division, and will be joined by his colleagues from Aerosure.

Over the last two years, the COVID-19 pandemic has created unprecedented disruption in the global aviation industry. It is expected that domestic and international flights will start to return gradually as countries reopen their borders and move to a new normal. WTW plays a key role in supporting the aviation industry globally with its expertise in understanding the sector’s key risks and concerns, managing complex challenges and advising aviation companies and operators on the optimal insurance coverage needed to meet their long-term risk management needs. This industry support extends to WTW’s Airport Risk Community (ARC), a knowledge sharing network that facilitates global connectivity between groups of professionals to help them understand and take action on emerging risks and industry trends.

Commenting on the acquisition, Head of Corporate Risk & Broking, Asia and Australasia, and Head of Australasia, Simon Weaver, said: “Aerosure is a leading aviation industry specialist with a large book of aviation focused industry clients, including airlines, airports and air traffic control, committed to the long-term position of its clients. Over the years, it has not only grown to become the pre-eminent specialist Aviation broker in the region but has contributed to the growth and development of the aerospace community in Australia and New Zealand.

WTW has worked in close partnership with Aerosure to provide services to local aviation clients for many years. We already know that the Aerosure team shares our values and ethos. Bringing them into WTW reflects our global strategy to work with high-performing and high-potential businesses in our chosen markets and industry sectors. With this acquisition, we see great opportunities in providing additional services and solutions to clients throughout Asia and Australasia, supporting companies and operators as they return to normality.”

John Rooley, CEO, Global Aerospace, WTW, added: “We are very excited by the deal and delighted that the highly talented Aerosure team is joining WTW. By combining the capabilities of Aerosure, this acquisition further expands the footprint of our aerospace business, enhancing our client offering both locally and globally as the teams work together with our aviation specialists in over 35 locations across the WTW network. The combination of our teams will strengthen our value proposition for our clients as a world-leading insurance broker and trusted risk adviser in the aerospace industry, providing them with a wide and deep range of solutions.”

Greg Rector, Managing Director, Aerosure, said: “We are delighted to take our partnership with WTW to the next level to provide added value to all of our aviation focused industry clients. This partnership has proven to be an industry leading proposition for all of our clients and we are extremely excited to be cementing our relationship for the benefit of all our clients across Australia, New Zealand and the Pacific Islands.”

The acquisition is effective immediately.

About Willis Towers Watson

Willis Towers Watson (NASDAQ: WLTW) is a leading global advisory, broking and solutions company that helps clients around the world turn risk into a path for growth. With roots dating to 1828, Willis Towers Watson has 45,000 employees serving more than 140 countries and markets. We design and deliver solutions that manage risk, optimise benefits, cultivate talent, and expand the power of capital to protect and strengthen institutions and individuals. Our unique perspective allows us to see the critical intersections between talent, assets and ideas – the dynamic formula that drives business performance. Together, we unlock potential. Learn more at

Media contact

Asia Pacific – Clara Goh: +65 6958 2542 | [email protected]
Australia and New Zealand – Claire King: +61 3 8681 9708 | [email protected]

Alibaba Group Announces CFO Succession

Alibaba Group Announces CFO Succession

Toby Xu named as CFO, Maggie Wu to continue as board director in planned transition

Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, “Alibaba” or “Alibaba Group”) today announced that Toby Xu, Deputy Chief Financial Officer, will succeed Maggie Wu as the Company’s Chief Financial Officer, effective April 1, 2022. Maggie will continue as a partner in the Alibaba Partnership and serve as an executive director on the Alibaba board.

“Maggie has made exceptional contributions that are instrumental to Alibaba’s achievements to date. Since joining Alibaba almost fifteen years ago, Maggie has helped lead three successful company public listings as CFO: on the Hong Kong Stock Exchange in 2007, and Alibaba Group Holding on the New York Stock Exchange in 2014 and on the Hong Kong Stock Exchange in 2019. She has built and nurtured a finance team with professional capabilities and accomplishments second to none, and has served as our bedrock in pursuing Alibaba’s strategies and business development. Maggie is forever calm and unflappable, regardless of ups and downs in the global capital markets and macro environment. She is humble and resilient, and has been my irreplaceable and closest partner over the years,” said Daniel Zhang, Chairman and CEO of Alibaba Group. “Going forward, Maggie will leverage her deep experience to support Alibaba in new ways. We will continue to benefit from her guidance and insights in her continued role as an Alibaba board director.”

“We are focused on the long-term, and succession within our management team on every occasion is always in the service of ensuring Alibaba will be stronger and better positioned for the future,” said Zhang. “Toby joined Alibaba from PwC three years ago and was appointed Deputy Group CFO in July 2019. He swiftly demonstrated his solid capabilities and leadership in response to our continually evolving businesses. He took on increasing responsibilities that grew to include our strategic investments, in addition to financial management and operations. We are certain that Toby is the right person to serve as our new Group CFO and, together with the core management team, will help lead our team towards our next success.”

“The announcement of Alibaba’s CFO transition today is the culmination of extensive preparation over many years and a part of Alibaba’s leadership succession planning. The markets will always have ups and downs, but Alibaba has ambitious long-term goals. We are in a relay race and we must have new generations of talent to take the company forward. I trust Toby even more than I trusted myself when I first took up the CFO position years ago. I am confident that Toby – through his professional capabilities and leadership skills, and together with Daniel and the core management team – will successfully lead our team into the future,” said Maggie Wu, Chief Financial Officer of Alibaba Group.

Toby joined Alibaba in July 2018 and was appointed Deputy Chief Financial Officer in July 2019. Before joining Alibaba Group, Toby was a partner at PricewaterhouseCoopers for 11 years, where he joined in 1996. He serves as a director of Sun Art Retail Group, Lianhua Supermarket Holdings and Red Star Macalline Group. Toby graduated from Fudan University in Shanghai, China, with a bachelor’s degree in Physics in 1996. He is a member of the Chinese Institute of Certified Public Accountants.

About Alibaba Group

Alibaba Group’s mission is to make it easy to do business anywhere. The company aims to build the future infrastructure of commerce. It envisions that its customers will meet, work and live at Alibaba, and that it will be a good company that lasts for 102 years.

Grace Shao

Alibaba Group

+852 9857 2779

[email protected]

Liyan Chen

Alibaba Group

+1 515 864 1116

[email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: Online Retail Data Management Retail Technology Software Internet



HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule —

— FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study


, and to support global registrations —

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed patient enrollment of FRESCO-2, a Phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer (“CRC”) in the U.S., Europe, Japan and Australia. The enrollment goal was reached on December 2, 2021.

FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival (“OS”). This large Phase III trial enrolled patients in over 150 sites in 14 countries. Additional details of the study may be found at, using identifier NCT04322539.

Dr. Marek Kania, EVP, Managing Director and Chief Medical Officer of HUTCHMED International Corporation, said, “HUTCHMED continues to execute on developing novel oncology medicines for patients worldwide despite the backdrop of the global pandemic. We would like to thank investigators, patients and their families for taking part in this study and we look forward to seeing the results of this study in patients with metastatic CRC, where there is a high unmet need for new treatment options.”

Topline results from the FRESCO-2 trial are expected to be reported in the second half of 2022 when the event-driven primary endpoint, OS, is mature. If positive, HUTCHMED would initiate plans to apply for marketing authorization of fruquintinib by the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”) and the Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”). The U.S. FDA granted Fast Track Designation for the development of fruquintinib for the treatment of patients with metastatic CRC in June 2020. Clinical data from the completed Phase III FRESCO study in Chinese patients, additional supporting studies in CRC and this FRESCO-2 global study, if positive, could support a future U.S. FDA New Drug Application (“NDA”) for the treatment of patients with advanced metastatic CRC (third-line and later). The FRESCO-2 study design was also reviewed and endorsed by the EMA and PMDA.

HUTCHMED retains all commercial rights to fruquintinib outside of China. In China, where fruquintinib is marketed under the brand name ELUNATE®, HUTCHMED is partnered with Eli Lilly and Company and is responsible for development and execution of all on-the-ground medical detailing, promotion and local and regional marketing. Fruquintinib is not approved for use outside of China.

About CRC

CRC is a cancer that starts in either the colon or rectum. CRC is the third most common cancer worldwide, estimated to have caused more than 915,000 deaths in 2020.2 In the U.S., an estimated 150,000 people will have been diagnosed with CRC and 53,000 people will have died from CRC in 2021.3 In Europe, CRC is the second most common cancer, with an estimated 507,000 new cases and 240,000 deaths in 2020.2 In Japan, CRC is the most common cancer, with an estimated 147,000 new cases and 59,000 deaths in 2020.2

About Fruquintinib

Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage. The generally good tolerability in patients to date, along with fruquintinib’s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.

About Fruquintinib Approval in China

Metastatic colorectal cancer in China: Fruquintinib was approved for marketing by the China National Medical Products Administration (NMPA) in September 2018 and commercially launched in China in late November 2018 under the brand name ELUNATE®. It was included in the China National Reimbursement Drug List (NRDL) in January 2020. ELUNATE® is indicated for the treatment of patients with metastatic CRC who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-EGFR therapy (RAS wild type). Results of the FRESCO study1, a Phase III pivotal registration trial of fruquintinib in 416 patients with metastatic CRC in China, were published in The Journal of the American Medical Association, JAMA, in June 2018 ( identifier: NCT02314819).

About Fruquintinib Development Beyond CRC Monotherapy

The safety and efficacy of fruquintinib for the following investigational uses have not been established and there is no guarantee that it will receive health authority approval or become commercially available in any country for the uses being investigated:

Gastric Cancer (“GC”) in China: In October 2017, HUTCHMED initiated the FRUTIGA study, a randomized, double-blind, Phase III trial evaluating the efficacy and safety of fruquintinib combined with paclitaxel for second-line treatment of advanced gastric or esophagogastric junction (“GEJ”) adenocarcinoma. The trial is designed to enroll patients who did not respond to first-line standard chemotherapy. Subjects receive either fruquintinib combined with paclitaxel or placebo combined with paclitaxel. Patients are randomized at a 1:1 ratio and stratified according to factors such as stomach vs. GEJ tumor type and performance status. The primary efficacy endpoint is OS. Secondary efficacy endpoints include progression-free survival (as defined by RECIST 1.1), objective response rate, disease control rate, duration of response, and quality-of-life score (EORTC QLQ-C30, version 3.0). Biomarkers related to the antitumor activity of fruquintinib will also be explored ( identifier: NCT03223376). In June 2020, HUTCHMED completed a planned interim data review. Based on the preset criteria, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue.

Immunotherapy combinations: HUTCHMED has entered into collaboration agreements to evaluate the safety, tolerability and efficacy of fruquintinib in combination with PD-1 monoclonal antibodies, including with tislelizumab (BGB-A317, developed by BeiGene, Ltd) and sintilimab (IBI308, developed by Innovent Biologics, Inc. and marketed as TYVYT® in China).

  • Metastatic breast and endometrial cancers in the U.S.: HUTCHMED initiated this open-label, multi-center, non-randomized, Phase Ib/II study in the U.S. to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced, refractory triple negative breast cancer (“TNBC”) and endometrial cancer (“EMC”). This study is being conducted to investigate if the addition of fruquintinib can potentially induce activity to immune checkpoint inhibitor therapy in TNBC and EMC. Additional details of the study may be found at, using identifier NCT04577963. Safety and preliminary efficacy of fruquintinib were demonstrated in advanced solid tumors, including TNBC, in a Phase I study conducted in China (NCT01645215) and a Phase I/Ib study is ongoing in the United States (NCT03251378).

  • Gastric, colorectal and non-small cell lung cancers in China & Korea: BeiGene, Ltd. initiated this open-label, multi-center, Phase II study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced or metastatic, unresectable GC, CRC or non-small cell lung cancer (“NSCLC”). Additional details of the study may be found at, using identifier NCT04716634.

  • Solid tumors in China: HUTCHMED initiated this open-label, multi-center, non-randomized, Phase II study to assess the safety and efficacy of fruquintinib in combination with sintilimab in patients with advanced cervical cancer, EMC, GC, hepatocellular carcinoma (HCC), NSCLC or renal cell carcinoma (RCC). Additional details of the study may be found at, using identifier NCT03903705. Preliminary results of certain cohorts were presented at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO) and the Chinese Society of Clinical Oncology Annual Meeting (CSCO).


HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/immunology. Since inception it has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of fruquintinib for the treatment of patients with advanced CRC and the further clinical development of fruquintinib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the sufficiency of clinical data to support NDA approval of fruquintinib for the treatment of patients with advanced CRC in the U.S., Europe, Japan, Australia or other jurisdictions, its potential to gain expeditious approvals from regulatory authorities, the safety profile of fruquintinib, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for fruquintinib, the timing of these events, and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. In addition, as certain studies rely on the use of other drug products such as paclitaxel, tislelizumab and sintilimab as combination therapeutics with fruquintinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, on AIM and on The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Investor Enquiries  
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries  
Americas – Brad Miles,
Solebury Trout
+1 (917) 570 7340 (Mobile)
[email protected]
Europe – Ben Atwell / Alex Shaw,
FTI Consulting
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
[email protected]
Asia – Zhou Yi,
+852 9783 6894 (Mobile)
[email protected]
Nominated Advisor  
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited
+44 (20) 7886 2500


1 Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496. doi:10.1001/jama.2018.7855.
2The Global Cancer Observatory. Accessed September 21, 2021.
3 SEER. Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Accessed September 21, 2021.

Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia

Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry Drugs Approved for Cardiovascular Risk Reduction in Diabetes

Key points:

  • Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest treatment benefit in major adverse cardiovascular events (MACE) of cardiovascular mortality or irreversible morbidity (non-fatal heart attack or stroke) in patients with diabetes and/or myocardial ischemia (72% of total treated population)  
  • This target population is at very high risk for mortality and irreversible morbidity due to micro- and macro-vascular disease despite receiving optimal standard of care therapies 1
  • Rexlemestrocel-L, added to optimal standard of care therapies, reduced the 3-point MACE composite of cardiovascular death or heart attack or stroke by 37% across all HFrEF patients with diabetes and/or ischemia and by 54% in HFrEF patients with systemic inflammation (elevated baseline hs-CRP)
  • United States Food & Drug Administration (FDA) has previously accepted 3-point MACE reductions of 12-14% for approval of multiple pharmaceutical industry drugs to reduce cardiovascular risk in diabetic patients 2,3
  • FDA confirmed that reduction in cardiovascular mortality or irreversible morbidity (non-fatal heart attack or stroke) is an acceptable clinically meaningful endpoint for determining the treatment benefit of rexlemestrocel-L for patients with HFrEF
  • Mesoblast to formally submit to FDA its new analyses of outcomes in high-risk HFrEF patients with diabetes and/or myocardial ischemia to agree on a potential pathway to approval.

NEW YORK, Dec. 05, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided new analyses from the landmark DREAM-HF Phase 3 trial showing that the greatest treatment benefit from rexlemestrocel-L is in HFrEF patients with diabetes and/or ischemia, who are at high-risk of cardiovascular mortality, heart attacks or strokes.

In recent guidance to Mesoblast, FDA confirmed that reduction in incidence of cardiovascular mortality or irreversible morbidity (non-fatal heart attack or stroke) is a clinically meaningful acceptable endpoint in patients with chronic HFrEF and encouraged Mesoblast to identify the highest-risk group with greatest likelihood of beneficial response to intervention with rexlemestrocel-L in the DREAM-HF Phase 3 trial.

In line with this guidance, Mesoblast performed additional analyses of MACE outcomes in pre-specified high-risk patient groups from the landmark DREAM-HF trial, and the results were presented December 3 by Chief Executive Dr Silviu Itescu at the 18th Global CardioVascular Clinical Trialists Forum (CVCT) in Washington DC.

The data showed that:

  • While a single rexlemestrocel-L dose on top of maximal standard of care therapies reduced the composite 3-point MACE in all 537 patients by 33% (p=0.02) over a mean follow-up of 30 months, a hierarchical analysis across pre-specified high-risk subgroups showed greatest benefit in patients with diabetes and/or myocardial ischemia (hazard ratio 0.63, p=0.019)
  • Among control patients with HFrEF (n=276) all of whom were treated with maximal available standard of care therapies, risk of 3-point MACE was 1.9-fold higher in controls with diabetes and/or myocardial ischemia (n=192) than controls with neither diabetes nor myocardial ischemia (n=84), p=0.02. This confirmed the ongoing high-risk of 3-point MACE in control patients with diabetes and/or myocardial ischemia due to micro- and macro-vascular disease despite receiving optimal standard of care therapies
  • Compared to control patients, rexlemestrocel-L reduced the incidence of 3-point MACE by 37% overall in NYHA class II or III HFrEF patients with diabetes and/or myocardial ischemia (n=385, p=0.02) and by 54% in those with diabetes and/or myocardial ischemia who had evidence of systemic inflammation, as defined by elevated baseline levels of hs-CRP >2mg/L (n=212, p=0.003).

Diabetes Mellitus is not only a significant risk factor in the onset of heart failure, it also increases the risk of mortality and morbidity in patients who have existing heart failure.1-3 Type 2 diabetes causes structural heart disease and heart failure through myocardial ischemia involving small and large vessels. Importantly, inflammation which is a critical component of the pathophysiology of the disease is also known to accelerate large vessel atherosclerosis.1

The 3-point composite MACE is an endpoint the FDA has previously accepted for approval of multiple drugs to reduce cardiovascular risk in diabetic patients. FDA guidance states that reliance on a single study to provide the substantial evidence of effectiveness necessary to support a Biologic License Application (BLA) is generally limited to situations in which a trial has demonstrated a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with potentially serious outcome for which confirmation of the result with a second trial would be practically or ethically impossible. Mesoblast will submit for formal FDA review the new data analyses showing the reduction in mortality and irreversible morbidity by rexlemestrocel-L in HFrEF patients with diabetes and/or myocardial ischemia, to agree on a potential pathway to approval.

About Mesoblast

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast


  1. Dunlay SM., et al. Circulation. 2019;140:e294–e324
  2. Wang CCL et al. Circulation 2019; 139: 1741-1743.
  3. McGuire DK et al. JAMA Cardiol. 2021; 6:148-158.

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. All statements other than statements of historical fact, including our intention to agree with FDA on a potential pathway to approval, are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. The risks, uncertainties and other factors that may impact our forward-looking statements include, but are not limited to: the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; whether the FDA agrees to a regulatory pathway; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. Unless required by law, we do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors

Paul Hughes Sumit Media
T: +61 3 9639 6036 Grant Titmus
E: [email protected] T: +61 419 388 161
  E: [email protected]
  Nadine Woloshin
  T: +1 917-699-9456
  E: [email protected]

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency

Event Scheduled for 8:00 a.m. ET Monday, December 6, 2021

PR Newswire

AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D).

Investors and the public are invited to listen to a live audio webcast of the conference call on December 6, 2021, at 8:00am ET, which can be accessed prior to the start of the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) Conference ID 13725511 or through the Events & Presentations section of the Company’s website.

About Aeglea BioTherapeutics 
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea’s lead product candidate, pegzilarginase, is in an ongoing Phase 3 pivotal trial in patients with Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit


Cision View original content to download multimedia:

SOURCE Aeglea BioTherapeutics, Inc.